$TTRX News
Last published 4d ago
- 4d agoTTRXTurn Therapeutics Inc. - PRESS RELEASE, DATED NOVEMBER 9, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 4d agoTTRXTurn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial ResultsBusiness WireWESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026. Additional Stage 1/Phase 2a results show encouraging response in the ...
- 3w agoTTRXU.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside ChatBusiness WireTurn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and
- 2mo agoTTRXTurn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation ForumBusiness WireTurn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and
- 2mo agoTTRXTurn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific OfficerBusiness WireBrings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing
- 2mo agoNBPTTRXNovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent DirectorGlobeNewswireMartin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience
- 2mo agoTTRXTurn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and ItchBusiness WireIn-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by
- 3mo agoTTRXTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial ResultsBusiness WireInterim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M.
- 3mo agoTTRXTurn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026Business WireTurn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic
- 4mo agoTTRXTurn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic DermatitisBusiness WireClinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as
- 4mo agoTTRXTurn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic DermatitisBusiness WireTurn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7,
- 5mo agoTTRXTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic DermatitisBusiness Wire92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9%
- 5mo agoTTRXTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory ModelBusiness WireStudy demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the
- 5mo agoTTRXTurn Therapeutics to Present at Jefferies Global Healthcare Conference 2026Business WireTurn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will
- 5mo agoTTRXTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory LeadBusiness WireDr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage
- 6mo agoTTRXTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesBusiness WirePhase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected Mid-2026 Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group Turn
- 7mo agoTTRXTurn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesBusiness WirePhase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026 Secured up to $25 Million in Growth Capital from Avenue Capital Group Strengthened Leadership Team via
- 7mo agoTTRXTurn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital GroupBusiness WireFinancing Extends Runway and Supports Continued Advancement of Atopic Dermatitis (Eczema) and Onychomycosis (Nail Fungus) Programs Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage dermatology company developing
- 8mo agoTTRXTurn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory AffairsBusiness WireNationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company's lead investigational therapy Turn Therapeutics, Inc. (NASDAQ:TTRX), a
- 9mo agoTTRXTurn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare ConferencesBusiness WireTurn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will
- 10mo agoTTRXTurn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsGlobeNewswireLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound
- 1y agoTTRXTurn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireSuccessfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and
- 1y agoTTRXTurn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.GlobeNewswireLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced
- 1y agoTTRXTurn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate CommunicationsGlobeNewswireLOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the
- 1y agoTTRXTurn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor MedlineGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and
- 1y agoTTRXTurn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic MilestonesGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and
- 1y agoTTRXTurn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025GlobeNewswireLOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (NASDAQ:TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming
- 1y agoTTRXTurn Therapeutics Appoints Dr. Kent Kester to Board of DirectorsGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective
- 1y agoTTRXTurn Therapeutics Appoints Arthur Golden to Board of DirectorsGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective
- 1y agoTTRXTurn Therapeutics to Commence Trading Today on NasdaqGlobeNewswireWESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective